- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07921992
Clinical Application Research of the Fully Automatic Biochemical System
By applying the fully automatic biochemical analysis system, samples such as serum, plasma, urine or other body fluids are tested. The test results are compared with clinical diagnoses or those of other analytical instruments produced by established manufacturers to evaluate indicators such as the accuracy, precision and correlation of the analyzer. Additionally, the differences in the same-source samples are analyzed and studied.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
No restrictions on audience
Description
Inclusion Criteria:
- During the research period, in accordance with the clinical application research plan of the fully automated sample processing system, the remaining clinical test samples that met the test results or corresponding clinical diagnoses were selected, including but not limited to serum, plasma, urine, etc. Approximately 2,900 samples that met the inclusion criteria for collection were provided, along with the test data and sample traceability information.
Exclusion Criteria:
- (1) Samples that do not meet the inclusion criteria; (2) Samples with unclear clinical diagnosis; (3) Test samples that are severely hemolyzed, deteriorated, contain chylous blood, or are significantly contaminated by microorganisms, etc., which do not meet the requirements.
Exclusion criteria
- Sample results of those that do not meet the inclusion criteria or those that meet the exclusion criteria but still underwent testing;
- Samples that did not complete the required tests for the complete trial or had missing data due to sample or instrument operation;
- When the test samples require re-testing due to human error, instrument failure, sample addition failure, etc., the re-tested results shall be taken as the standard, and the reasons for re-testing shall be recorded.
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
sensitivity
Time Frame: 2026.11.01-2030.12.30
|
2026.11.01-2030.12.30
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NanjingFirst-LAB-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.